We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03847389
Recruitment Status : Terminated (Difficulty in enrollment and COVID-19 pandemic.)
First Posted : February 20, 2019
Results First Posted : June 23, 2021
Last Update Posted : June 23, 2021
Sponsor:
Collaborators:
Synteract, Inc.
Covance
Information provided by (Responsible Party):
Hill Dermaceuticals, Inc.

Brief Summary:

Open-Label Study designed to evaluate the HPA axis suppression potential of Clobetasol Topical Oil and pharmacokinetic safety / systemic exposure to clobetasol when Clobetasol Topical Oil is applied to pediatric subjects with moderate to severe atopic dermatitis (AD) under maximal use conditions.

The study duration for each subject will be up to 54 days (up to 38 days for Screening assessments, followed by up to 16 days of treatment and follow-up). Additional time will be required for subjects requiring additional hypothalamic-pituitary-adrenal [HPA] axis function testing due to an abnormal result at End of Treatment.


Condition or disease Intervention/treatment Phase
Atopic Dermatitis Drug: Clobetasol propionate 0.05% Topical Oil Phase 1 Phase 2

Detailed Description:

This study is a multicenter, open-label study designed to evaluate the HPA axis suppression potential and systemic exposure to clobetasol, when administered as Clobetasol Topical Oil in pediatric subjects, under conditions consistent with anticipated clinical use and under conditions designed to maximize the potential for drug absorption in subjects with moderate to severe AD. The study will consist of three successively younger pediatric cohorts, as safety data allow:

  • Cohort 1: ≥12 to <18 years;
  • Cohort 2: ≥6 to <12 years; and
  • Cohort 3: ≥2 to <6 years. Enrollment into each successively younger pediatric cohort will proceed only after the preceding cohort has been completed and safety and exploratory data (including adverse events [AEs], tolerability assessments, clinical laboratory results, and the percentage of subjects with HPA axis suppression) have been reviewed and agreed to be acceptable for progression to the next cohort. Enrollment into Cohorts 2 and 3 will proceed only if the percentage of subjects with HPA axis suppression in Cohorts 1 and 2, respectively, is ≤40%. HPA axis suppression is defined as a cortisol concentration ≤18 µg/100 mL at approximately 30 minutes after stimulation with cosyntropin.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: open-label, maximal use, in 3 successive age cohorts
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-Label Study of the Pharmacokinetics and Safety Including HPA Axis Suppression Potential of Clobetasol Topical Oil in Pediatric Subjects With Moderate to Severe Atopic Dermatitis
Actual Study Start Date : September 9, 2019
Actual Primary Completion Date : May 2, 2020
Actual Study Completion Date : July 28, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eczema

Arm Intervention/treatment
clobetasol propionate topical oil
clobetasol propionate 0.05% topical oil applied as thin film twice daily for 2 weeks
Drug: Clobetasol propionate 0.05% Topical Oil
thin film application of the oil twice daily
Other Name: clobetasol propionate topical solution




Primary Outcome Measures :
  1. Number of Participants With HPA Axis Suppression - Serum Cortisol Concentration (Cortrosyn Stimulation Test) [ Time Frame: day 0 and day 15. ]
    30-minute Post-stimulation cortisol level ≤18 µg/100 mL at Day 0 means subject is not enrolled; 30-minute Post-stimulation cortisol level ≤18 µg/100 mL at end of treatment (Day 15) means subject had suppression.

  2. Adverse Events, Including Treatment Emergent Adverse Events (TEAEs) [ Time Frame: Days 0, 1, 8 and 15 ]
    number of events and percentage of subjects with AEs including TEAEs


Other Outcome Measures:
  1. ISGA Category [ Time Frame: Days 0, 1, 8 and 15 Efficacy assessment, including ISGA, was not performed due to premature termination of the study. ]

    ISGA results will be summarized at each visit as:

    1. number and percentage of subjects in each ISGA category
    2. number and percentage of subjects with an ISGA score of either 0 or 1 (clear or almost clear)
    3. number and percentage of subjects with an ISGA improvement of at least 2 grades from Baseline to each post-baseline evaluation
    4. number and percentage of subjects with an ISGA score of either 0 or 1 (clear or almost clear) and an improvement of at least 2 grades from Baseline to each post-Baseline evaluation

  2. Assessment of Burning/Stinging, Skin Atrophy, Striae, Folliculitis, and Telangiectasias (Tolerability Parameters). [ Time Frame: Days 1, 8 and 15 ]
    The subject will rate the sensation of burning/stinging within the past 24 hours as none (0), mild (1), moderate (2) or severe (3), and the Investigator will assess skin atrophy, striae, folliculitis, and telangiectasias, as absent (0) or present (1).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female subjects in good general health confirmed by medical history.
  • Subjects with a clinical diagnosis of AD (according to the criteria of Hanifin and Rajka) of moderate to severe intensity (ISGA score of 3 or 4) involving ≥25% to ≤50% of total BSA located within treatable areas (Cohort 1), or ≥35% to ≤50% of total BSA located within treatable areas (Cohorts 2 and 3), with treatable areas including all but the face, axillae, groin, and scalp.
  • Subjects with a normally functioning HPA axis, defined as a prestimulation serum cortisol level >5 µg/100 mL, and a response to cosyntropin stimulation to >18 µg/100 mL (after approximately 30 minutes); both blood draws for this test should be performed in the morning, if possible
  • Female subjects of childbearing potential must have a negative urine pregnancy test, must not be breastfeeding, and must agree to use an acceptable form of birth control for the duration of the study. Female subjects of childbearing potential are defined as all female subjects who have reached menarche and are not two years postmenopausal or who have reached menarche and have not had a hysterectomy, bilateral tubal ligation, and/or complete bilateral oophorectomy

Exclusion Criteria:

  • Subjects who do not have a normally functioning HPA axis (as defined in the inclusion criteria).
  • Subjects with an abnormal sleep schedule or who work at night.
  • Subjects who have used topical dermal corticosteroids or topical immunomodulators (e.g., tacrolimus or pimecrolimus) within 3 weeks before Day 1, and subjects who are using any systemic medication known to affect cortisol levels or HPA axis integrity, systemic corticosteroids, an acute systemic course of corticosteroids, and/or any biological medication within 30 days before Day 1.
  • Subjects with concomitant medical or dermatologic disorders (neurodermatitis, skin atrophy, striae, telangiectasia, etc.) that may interfere with study objectives and/or evaluations.
  • Subjects with active skin infection.
  • Subjects with any known significant endocrinological disorder that may require prohibited treatment, any known underlying disease that the investigator deems uncontrolled and poses a safety risk for the subject while participating in the study, known sensitivity to any ingredient of the study preparation, or a history of adverse responses to topical or systemic steroid therapy.
  • Subjects who are pregnant or nursing.
  • Subjects who have used bleach baths, phototherapy, and/or tanning beds, and/or who have had excessive sun exposure within 1 week before Day 1 and/or are planning to use any of these during the study.
  • Subjects who have participated in a clinical drug or device research study and/or used any investigational treatment within the last 30 days before Day

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03847389


Locations
Layout table for location information
United States, Florida
International Clinical Research - US, LLC
Sanford, Florida, United States, 32771
United States, Georgia
AeroAllergy Research Laboratories of Savannah, Inc
Savannah, Georgia, United States, 31406
United States, Pennsylvania
Paddington Testing Co., Inc.
Philadelphia, Pennsylvania, United States, 19103
United States, South Carolina
Spartanburg Medical Research
Spartanburg, South Carolina, United States, 29303
United States, Texas
Progressive Clinical Research
San Antonio, Texas, United States, 78213
United States, Virginia
Clinical Research Partners, LLC
Richmond, Virginia, United States, 23220
Sponsors and Collaborators
Hill Dermaceuticals, Inc.
Synteract, Inc.
Covance
Investigators
Layout table for investigator information
Study Director: Rosario G Ramirez, MD Hill Dermaceuticals, Inc.
  Study Documents (Full-Text)

Documents provided by Hill Dermaceuticals, Inc.:
Study Protocol  [PDF] January 28, 2019
Statistical Analysis Plan  [PDF] August 4, 2020

Layout table for additonal information
Responsible Party: Hill Dermaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT03847389    
Other Study ID Numbers: CP0418 SS-P2 051
First Posted: February 20, 2019    Key Record Dates
Results First Posted: June 23, 2021
Last Update Posted: June 23, 2021
Last Verified: January 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Dermatitis, Atopic
Dermatitis
Eczema
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Clobetasol
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs